Stomach/Gastric Cancer Treatment in Gurugram, Gurgaon, Haryana, Delhi

Global Metastatic Gastric Cancer Treatment Market: OverviewGastric cancer (GC) is the second-leading cause of cancer-related mortality worldwide and is also responsible for a significantly high cancer burden, as measured by disability-adjusted life years lost.

The World Health Organization estimates that in 2018, gastric cancer accounted for 783,000 deaths worldwide.

Approximately 50 to 65% of GC patients present with locally advanced or metastatic disease, and the majority would have systemic disease at some time during the course of their illness.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=80552Gastric cancer incidence and mortality are highly variable by region and highly dependent on diet and Helicobacter pylori infection.

In developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females.Key Drivers and Restrains of Global Metastatic Gastric Cancer Treatment MarketFavorable reimbursement in developed countries, adoption of combination therapy such as chemotherapy with immunotherapy drugs that effectively work in the stage III or IV gastric cancer.

Doctors are also opting for chemotherapy before surgery, called neoadjuvant therapy, or after surgery, called adjuvant therapy to treat metastatic gastric cancer, which is likely to drive the metastatic gastric cancer treatment market.However, low survival rate of metastatic gastric cancer and high cost associated with the immunotherapy treatment procedures are likely to restraint the market during the forecast periodRequest COVID Analysis on Metastatic Gastric Cancer Treatment Market –  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=80552North America to Account for Major Share of Global Metastatic Gastric Cancer Treatment MarketIn terms of region, the global metastatic gastric cancer market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & AfricaNorth America is projected to dominate the global market during the forecast period.

The region is anticipated to account for a significant share of the global market due to wide availability of immunotherapy drugs and favorable reimbursement scenario.The market in Asia Pacific is driven by sustainable growth trends across all clinical fields in countries in the region and consequent increase in number of cases.

 ASCO Abstracts 2020 ASCO: Results of IMpower110 studyAbstract No : 9594Abstract Type : Poster SessionIndication : Non-Small Cell Lung CancerIntervention : Atezolizumab (atezo) vs chemotherapyCompany : F. Hoffmann-La Roche, LtdTechnology : Monoclonal antibodyQLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits.

TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration.

Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms.Read More: https://www.delveinsight.com/asco-conference/article/NCT02409342 ASCO: Results from CARTITUDE-1Abstract No : 8505Abstract Type : Oral Abstract SessionIndication : Multiple MyelomaIntervention : JNJ-4528Company : Janssen Research & Development, LLCTechnology : CAR T Cell TherapyJNJ-4528 treatment led to responses in all pts.

These responses were early, deep, and durable at a low dose of CAR-T cells with 26/29 (90%) pts progression free at median 9-mo follow-up.

CRS was manageable in most pts, supporting outpatient dosing.View More: https://www.delveinsight.com/asco-conference/article/NCT03548207 ASCO: Results of IMvigor130Abstract No : 5011Abstract Type : Clinical science symposiumIndication : Urothelial CarcinomaIntervention : AtezolizumabCompany : RocheTechnology : Monoclonal antibodyThese results reinforce the potential predictive nature of biomarkers associated with response/resistance to atezo and highlight potentially distinct biology driving benefit with atezo and atezo + PBC.

These findings suggest a possible biomarker-directed approach to 1L mUC tx that warrants mechanistic interrogation and prospective validation.Read More: https://www.delveinsight.com/asco-conference/article/imvigor130 ESMO Conference 2020: CheckMate-649 Results at ESMO 2020Abstract No : Abstract: #LBA6Indication : Gastric Cancer, Gastroesophageal junction cancer and Esophageal CancerIntervention : NivolumabCompany : Bristol-Myers SquibbTechnology : PD-1/PD-L1 inhibitorCheckMate-649NIVO is the first PD-1 inhibitor to demonstrate superior OS and PFS in combination with chemo vs chemo alone in previously untreated pts with advanced GC/GEJC/EAC, with a manageable safety profile.

The global gastric cancer drugs market accounted approximate USD 3.6 billion in 2020 and it is expected to reach USD 13.3 billion by 2030 with a CAGR of 13.80% during forecast period.During the COVID-19 epidemic, the life sciences industry has played a critical role.

Governments, health systems, payers, retail pharmacies, and charities are increasingly collaborating with the pharmaceutical industry to offer extensive distribution and management.

While pharmaceutical innovation is saving the globe, biopharma and medtech firms now have a chance to keep up the trend.Browse Full report on Global Gastric Cancer Drugs Market at https://www.decisionforesight.com/reports/gastric-cancer-drugs-marketMarket Dynamics and Factors:The life sciences business has seen exponential development in terms of breadth and capabilities across the value chain.

The need for significant collaboration between life sciences and healthcare firms, not just on goods but also on solutions, to assist solve the demand-supply mismatch is one of the sector's main issues.

Universal health care systems are vast, complicated, and expensive to run.

Governments in both developed and emerging markets have made deliberate decisions to confront producers and demand more access to lower-cost medications.

Breast cancer is a disease in which cells in the breast grow out of control.

There are different kinds of breast cancer.

Know what is breast cancer, symptoms of breast cancer, breast cancer symptoms in Hindi, treatment for breast cancer, etc.

Watch this video by Dr. Priya Tiwari, Senior Consultant - Medical Oncologist, cancer doctor & cancer specialist  in gurugram Breast Cancer Treatment in Gurugram